Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00174-6/fulltext “The GBD 2021 anaemia estimates both provide a timely reminder that monitoring the prevalence of anaemia alone is insufficient to monitor the effects of this condition and help to identify potential unmet needs for prioritisation.”“The GBD 2021 anaemia estimates both provide a timely reminder that monitoring the prevalence of anaemia alone is insufficient to monitor the effects of this condition and help to identify potential unmet needs for prioritisation.” https://www.thelancet.com/journals/lanhae/home